Table 4.
Subgroups of asthma patients | ||||
---|---|---|---|---|
persistent asthma | ||||
1-intermittent n-10 |
2-mild n-14 |
3-moderate n-12 |
4-severe n-4 |
|
CD4+/IL-2+ | 7.5 ± 0.9 (3.2 ± 0.5) |
7.5 ± 0.6 (2.8 ± 0.3) |
9.1 ± 0.6 (2.3 ± 0.2) |
6.9 ± 0.5 (3.0 ± 0.0) |
CD4+/IL-4+ | 9.1 ± 1.1 (3.1 ± 0.3) |
9.1 ± 0.4 (3.9 ± 0.5) |
9.6 ± 0.4 (3.0 ± 0.4) |
7.0 ± 0.41 (3.5 ± 0.3) |
CD4+/IL-10+ | 7.1 ± 0.9 (5.0 ± 0.9) |
8.9 ± 0.9 (3.5 ± 0.5) |
8.5 ± 0.8 (3.0 ± 0.4)** |
11.2 ± 0.2 (5.2 ± 0.2) |
CD4+/IL-13+ | 11.5 ± 0.9 (4.0 ± 0.9) |
13.0 ± 0.7 (3.5 ± 0.3) |
13.3 ± 0.5 (3.4 ± 0.3) |
15.2 ± 0.2* (5.2 ± 0.2) |
CD4+/IFN-γ + | 6.8 ± 1.3 (3.3 ± 0.5) |
7.9 ± 0.7 (3.0 ± 0.3) |
7.0 ± 0.5 (2.7 ± 0.2) |
7.2 ± 0.2 (3.0 ± 0.0) |
CD4+/TNF-α + | 8.0 ± 0.9 (3.1 ± 0.3) |
8.5 ± 0.5 (3.1 ± 0.2) |
6.5 ± 0.6 (2.9 ± 0.1) |
8.0 ± 0.4 (3.7 ± 0.0) |
CD8+/IL-2+ | 7.5 ± 1.0 (3.5 ± 0.5) |
8.5 ± 0.8 (3.5 ± 0.4) |
7.3 ± 0.7 (3.1 ± 0.2) |
9.2 ± 0.2 (4.7 ± 0.2) |
CD8+/IL-4+ | 8.2 ± 0.9 (3.7 ± 0.5) |
8.6 ± 0.4 (3.6 ± 0.3) |
9.3 ± 0.4 (3.0 ± 0.2) |
8.2 ± 0.2 (3.5 ± 0.2) |
CD8+/IL-10+ | 7.5 ± 0.8 (3.8 ± 0.5) |
9.7 ± 1.0 (4.3 ± 0.6) |
8.2 ± 0.6 (3.3 ± 0.4) |
10.0 ± 0.0 (2.2 ± 0.2) |
CD8+/IL-13+ | 12.8 ± 0.9 (4.4 ± 0.6) |
13.4 ± 0.7 (4.9 ± 0.7) |
12.2 ± 0.5 (3.4 ± 0.3) |
14.0 ± 0.5 (5.2 ± 0.7) |
CD8+/IFN-γ + | 7.14 ± 1.0 (3.5 ± 0.9) |
8.6 ± 0.91 (3.0 ± 0.3) |
7.1 ± 0.6 (2.9 ± 0.3) |
6.0 ± 0.0 (3.0 ± 0.0) |
CD8+/TNF-α + | 7.57 ± 0.87 (3.7 ± 0.6) |
9.1 ± 0.9#
(3.4 ± 0.4) |
6.3 ± 0.6 (3.6 ± 0.4) |
7.2 ± 0.2 (3.0 ± 0.0) |
*P < .04 severe persistent asthma versus intermittent asthma.
**P < .05 severe persistent asthma versus moderate persistent asthma.
P-values from Mann-Whitney U-test.
Data as shown as mean ± SE.